Anteris Technologies Global Corp. (AVR): Results for announcement to the market Name of entity

Anteris Technologies Global Corp. (AVR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Results for announcement to the market Name of entity: Anteris Technologies Global Corp. (“ATGC”) ARBN: 677 960 235 Reporting period: For the quarter ended September 30, 2026 The attached Form 10-Q Quarterly Report for the quarter ended September 30, 2026 (the “Form

Original reporting
Published Nov 10, 2026, 11:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 11:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$AVR
Neutral
medium confidence
Mentioned
$AVR
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AVRNeutralLow
01

Why it matters

The filing is a routine earnings update for a small‑cap biotech; without specific financial metrics, market impact is expected to be modest.

02

Market read

Primary relevance is to investors in AVR; broader market effect is minimal.

03

What to watch

Related‑party payments of $576 k may hint at higher operating costs; the lack of disclosed revenue or profit figures leaves uncertainty.

Relevance 7/10Novelty 6/10Timing: filing date Nov 10 2026
AlphAI · Earnings readAVR · Q3 2026 · ended 2026-09-30

Anteris files Q3 2026 supplementary disclosure with related-party payments of US$576 thousand; no results table in this exhibit

→Mixed quarter

This Exhibit 99.1 contains no revenue, margin, earnings, cash flow or guidance figures. The only quantified item is the related-party payments disclosure, so no operating verdict can be supported from this document. The verdict is set to mixed as a neutral placeholder, not as a view on performance.

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Aggregate payments to related parties and their associates, Q3 2026other$576K––

What to watch

  • The Form 10-Q for the quarter ended September 30, 2026, which the release says has been filed with the SEC, for the full set of U.S. GAAP financial statements.
  • The ASX announcement 'Anteris Announces Results for the Third Quarter of 2026', which the release says was lodged with the ASX on November 11, 2026.
  • Any forward-looking guidance in the results announcement, which is not contained in this exhibit.

Balance sheet and cash flow

  • Payments to related parties and their associates of US$576 thousand in Q3 2026 were included in cash flows from operating activities.
  • No payments to related parties or their associates were included in cash flows from investing activities.

Analysis

This filing is a supplementary disclosure furnished under Item 2.02 alongside a Form 10-Q for the quarter ended September 30, 2026. It states that the 10-Q contains the condensed consolidated financial statements prepared under U.S. GAAP and denominated in U.S. dollars, but the statements themselves are not reproduced in this exhibit. As a result, the document contains no revenue, gross margin, operating expense, operating income, net income, EPS, cash, debt or guidance figures.

The one quantified item is the aggregate amount of payments to related parties and their associates in the third quarter of 2026, which the company puts at US$576 thousand. The company states that the amount includes fees paid to non-executive directors and salary payments to the CEO, President and CFO. It also states that these payments were included in operating cash flows, and that there were no related-party payments in investing cash flows. No prior-period comparison for this item is printed, so no change can be shown.

The release refers readers to two other documents for business activity and results: the Form 10-Q and an ASX announcement dated November 11, 2026. Neither is included in the text provided, so no assessment of demand, product volumes, margins, cash position or outlook can be made from this filing. The date of the ASX announcement is also later than this filing's timestamp of November 10, 2026, which the reader should keep in mind when matching the two documents.

For this read, the relevant figures are the 10-Q and the ASX results announcement. Until those are reviewed, the only verifiable statement about the period is the related-party payment figure and its classification within operating cash flows.

Not in the filing

stated, not guessed
  • Total revenue and all revenue sub-lines for Q3 2026, and prior-year and prior-quarter comparatives.
  • Cost of sales, gross margin, operating expenses (R&D, SG&A, other), and operating income for Q3 2026.
  • Net income or loss, GAAP and non-GAAP EPS, interest and tax for Q3 2026.
  • Segment or geographic revenue breakdown.
  • Operating, investing and free cash flow totals, cash balance, debt, total assets and equity.
  • Capital returns such as share repurchases or dividends, if any.
  • Operating KPIs, such as procedure or unit volumes, if disclosed.
  • Any forward-looking guidance for revenue, gross margin, operating expenses or tax rate.
  • Prior-year and prior-quarter comparatives for the related-party payments figure.
  • The full text of the Form 10-Q, which the release says was filed but is not included.
  • The full text of the ASX announcement 'Anteris Announces Results for the Third Quarter of 2026', which the release says was lodged on November 11, 2026.
  • Management quotes, since the exhibit contains no executive commentary.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Anteris Technologies Global Corp. (NASDAQ: AVR) filed a Form 8‑K announcing its Q3 2026 results and related‑party payments, the first public disclosure of this quarter.

Company-level read

Ticker impact

$AVRNeutralMedium confidence
Context

SEC Form 8‑K reports Anteris Technologies' Q3 2026 results and related‑party payments of $576 k, the first public disclosure of this quarter.

Expected impact

likely limited movement as investors await detailed financials; modest pressure if results miss expectations

Evidence & confidence

The filing is a routine earnings report for a small‑cap biotech; without earnings numbers or guidance, market reaction is expected to be muted.

Market effects

Provides a data point for the structural‑heart‑device sector but unlikely to shift sector sentiment.

Minor impact on US and Australian biotech markets; no broader regional effect.

Limited to investors tracking small‑cap medical‑device stocks.

Counterpoint

If the company’s detailed financials later reveal a revenue shortfall, the stock could face a sharper decline than anticipated.

Key entities

  • Anteris Technologies Global Corp.

    Global healthcare company developing structural‑heart devices, listed on NASDAQ under AVR.

Every AVR earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$AVRMedAI 8/10

Anteris Reports Strong One-Year Results For DurAVR Heart Valve In High-Risk Aortic Stenosis Patients

Anteris Technologies (AVR) reported one-year data for its DurAVR heart valve, showing strong performance in high-risk aortic stenosis patients. Key metrics include 1% hospitalization for heart failure, 8.9 mmHg mean pressure gradient, and 96% of patients with mild or no symptoms post-treatment. The study involved 100 patients with complex conditions. Anteris stock closed at $4.99, up to $5.09 in after-hours trading.

$AVRMedAI 8/10

Small Cap watch: ASX small caps ease after strong week as NewPeak, Orthocell and Anteris advance drilling, sales and data

The S&P/ASX Small Ordinaries Index fell 0.74% on Friday but gained 3.03% over the week. NewPeak Metals completed drilling in Argentina, Orthocell reported record US sales, and Anteris Technologies released positive heart valve data. NewPeak tested gold mineralization, Orthocell sold 92 units of Remplir, and Anteris' valve showed improved haemodynamics in 22 patients.

$AVRMedAI 8/10

Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026

Anteris Technologies (NASDAQ: AVR, ASX: AVR) reported 30-day outcomes for its DurAVR THV in 22 patients with medium aortic annuli, showing positive hemodynamic and safety results. The DurAVR THV is being evaluated in the ongoing PARADIGM trial, a global study comparing it to commercially available TAVRs. The company aims to confirm the valve's effectiveness in a randomized setting.